Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Article from MarketBeat Pfizer Adds to Its Big Bet on Weight Loss DrugsWritten by Jordan Chussler. Published 12/16/2025. 
Key Points - The health care sector has led the S&P 500 over the three months, but Pfizer has lagged of late, slipping 5% since the start of October.
- As the Big Pharma company continues to struggle to replace COVID-19 vaccine revenue, it is heavily learning into the semaglutide and GLP-1 weight loss drug trend.
- Last week, the company signed a $2.1 billion licensing agreement with a Chinese pharma company to develop its early-stage weight loss pill.
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays. Pfizer (NYSE: PFE), the maker of Chantix, Eliquis and Paxlovid, has seen its shares slide 5% since the start of October. By comparison, other mega-cap pharmaceutical companies, including Johnson & Johnson (NYSE: JNJ), Regeneron Pharmaceuticals (NASDAQ: REGN) and Eli Lilly (NYSE: LLY), are up roughly 14%, 24% and 25%, respectively, over the same period. Recent changes in U.S. digital currency policy could have far-reaching implications for how money moves through the financial system.
A new analysis explores how emerging stablecoin regulations may reshape banking, deposits, and retirement planning — and why some experts believe individuals should understand these shifts sooner rather than later. The report also outlines strategies investors are using to prepare for potential structural changes in the monetary landscape. Get the free retirement protection guide here Despite Pfizer making headlines on Nov. 13 after acquiring obesity biotech Metsera in a $10 billion deal, the stock has only managed a 0.23% gain since then. The nearly 177-year-old biopharma company is once again looking to expand its role in the weight loss drug market, with both management and shareholders hoping that the move can help recover revenue lost as demand for mRNA-based COVID-19 vaccines wanes. Pfizer Looks to Gain Market Share After Enormous Deal With YaoPharma On Tuesday, Dec. 9, Pfizer struck a $2.1 billion licensing deal with China's YaoPharma to develop a GLP-1 weight loss pill that is in early-stage development. The drug works similarly to Wegovy, the game-changing weight loss injection from competitor Novo Nordisk (NYSE: NVO). While news of a yet-to-be-approved weight loss pill may not move the stock in the short term, it does reflect the company's commitment to the obesity treatment market. The agreement includes a $150 million upfront fee to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, which has an $8.4 billion market cap. Pfizer could also pay YaoPharma up to $1.94 billion in milestone payments tied to development and regulatory progress, plus royalties on sales if the drug is approved. Those milestone payments will be contingent on YaoPharma successfully navigating the weight-loss pill through phase one trials, with Pfizer taking control of later-stage development. Pfizer also plans combination studies — currently in mid-stage development — pairing the Chinese firm's pill with Pfizer's own GIP-targeting therapy, mirroring Eli Lilly's approach with Zepbound and Mounjaro that targets both GLP-1 and GIP. Pfizer Is Positioning Itself for the Future of the Weight Loss Drug Market The deal underscores how aggressively the company's executives are pursuing a more prominent, long-term position in the GLP-1 and broader obesity treatment market. Pfizer's leadership has shown a willingness to invest roughly $10.1 billion over the past month as it targets a rapidly growing industry. Forecasts from market analysis firm Grand View Research suggest the GLP-1 weight loss drug market could grow at a compound annual growth rate (CAGR) of about 18.54% from 2025 to 2030, expanding from under $14 billion at the start of this year to roughly $48.84 billion by 2030. Grand View Research found that North America accounts for the largest revenue share, representing more than 75% of the GLP-1 agonists market. While alternative obesity interventions exist — including lifestyle changes and bariatric surgery — GLP-1 drugs remain the preferred option for many physicians and patients. Patient Investors Can Enjoy PFE's Sizable Dividend Shareholders are hoping Pfizer's push into the weight loss drug market pays off after the stock has punished loyal investors with a loss of more than 31% over the past five years. Much of that decline stems from reduced COVID vaccine sales, which caused revenue growth to fall from more than 95% at the end of 2021 to a decline of over 41% by the end of 2023. Last year, Pfizer registered a modest rebound, with revenue rising nearly 7%. The stock's dividend has helped offset some investor concerns: Pfizer remains a strong dividend payer with a current yield of 6.65% — or $1.72 per share annually. The payout has increased for 16 consecutive years, making the stock attractive to income investors despite a 100% dividend payout ratio that raises some questions. For investors willing to forgo short-term gains and bet on the near- and mid-term prospects of prescription weight loss drugs, Pfizer can provide income and serve as a speculative way to participate in the GLP-1 market. That said, growth-focused investors may be wary after another year of lackluster performance. Analysts' average 12-month price target implies just over 10% upside from the current price and carries a consensus Hold rating. Meanwhile, short interest has been steadily rising as the stock continues to attract bears. Currently, about $3.58 billion of the float is shorted — nearly 84% more than PFE's short position at the end of January 2025.
| 
